1BIIB:BIT
Biogen Inc
€180.88
arrow_downward
-1.41%(-2.58) 1D
Sep 9, 5:26:00 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 1BIIB...
Open
€181.28
High
€181.28
Low
€180.88
Mkt. cap
31.14B
Avg. vol.
14.00
Volume
80.00
52-wk high
€196.02
52-wk low
€116.50
No. of employees
8K
Open
€181.28
High
€181.28
Low
€180.88
Mkt. cap
31.14B
Avg. vol.
14.00
Volume
80.00
52-wk high
€196.02
52-wk low
€116.50
No. of employees
8K
News stories
From web sources and news partners
CNBC
·
6 hours ago
Biogen CEO: We are at that inflection point where we are on a path to sustainable revenue growth
Investing.com
·
7 hours ago
Biogen at Wells Fargo healthcare conference: growth bets widen
Simply Wall Street
·
17 hours ago
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com